Alnylam Pharmaceuticals (alny 1 09/15/27)
13F holders, Q4 2024 (December 31)9holders +1
2new positions
1sold out
$1.06avg. 13F price*
At the end of Q4 2024, 9 institutions reported holding Alnylam Pharmaceuticals (alny 1 09/15/27) in their 13F filings, up 1 from Q3 2024. 2 opened new positions and 1 sold out. The largest holders were BNP PARIBAS ASSET MANAGEMENT Holding S.A. ($5.3M), Angelo Gordon & Co., L.P. ($3.7M) and Toronto Dominion Bank ($3.2M).
- Company
- Alnylam Pharmaceuticals (alny 1 09/15/27)
- CUSIP
- 02043QAB3
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $6.9M |
| Exits | 1 | $19.8M |
All 13F filers, Q3 2024 → Q4 2024: 6,500,000 shares bought and 203,923 shares sold, net +6,296,077 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.01% | No change | 4,950,000 | $5.3M |
| Angelo Gordon & Co., L.P. | 0.94% | New | 3,500,000 | $3.7M |
| Toronto Dominion Bank | 0.01% | New | 3,000,000 | $3.2M |
| Bank of New York Mellon Corp | 0.00% | Reduce -16.7% | 500,000 | $534K |
| Sei Investments Co. | 0.00% | No change | 99,000 | $105K |
| Oppenheimer Asset Management Inc. | 0.00% | Reduce -8.2% | 78,000 | $83K |
| Stephens Inc. | 0.00% | Reduce -48.8% | 22,000 | $23K |
| Boussard & Gavaudan Investment Management LLP | 0.00% | Reduce -38.1% | 6,500 | $7K |
| EverSource Wealth Advisors, LLC | 0.00% | No change | 3,000 | $3K |
"% of holder's portfolio" is ALNYLAM PHARMACEUTICALS (ALNY 1 09/15/27)'s weight in each manager's 13F, not the share of Alnylam Pharmaceuticals (alny 1 09/15/27) the manager owns.